摘要
【目的】了解吗替麦考酚酯（MMF）联合雷公藤多甙治疗IgA肾病的临床疗效。【方法】经肾穿刺活检并结合临床确诊为原发性IgA肾病39例，随机分戍两组，试验组20例，服用吗替麦考酚酯及雷公藤多甙；对照组19例，单用吗替麦考酚酯。【结果】经治疗24周后，吗替麦考酚酯联合雷公藤多甙治疗组的完全缓解率及总有效率分别为55％和85％，明显高于吗替麦考酚酯组（分别为47．4％和73．7％），且差异有显著性（P〈0．05）；两组间对应的24h尿蛋白定量、血浆白蛋白、血总胆固醇相比较有显著性差异（P〈0．05），血肌酐两组相比无显著性差异（P〉0．05）。【结论】吗替麦考酚酯联合雷公藤多甙治疗IgA肾病临床疗效肯定。
[Objective] To explore the clinical efficacy of mycophenolate mofetil（MFF） combined with tripterygium glycosides for the treatment of IgA nephropathy. [Methods] Thirty nine cases of IgA nephropathy confirmed by renal biopsy were randomly divided into 2 groups. Experiment group （ n = 20） was given MFF combined with tripterygium glycosides. Control group（ n = 19） was given MFF alone. [Results] At 24 weeks after treatment, the complete remission rate and total effective rate in experiment group were 55% and 85%, respectively, which were markedly higher than those in control group（47.4% and 73.7 %, respectively）, and there was significant difference（ P 〈0.05）. There were significant differences in 24-hour urine protein, serum albumin and total cholesterol between two groups（ P 〈0.05）, but there was no significant difference in serum creatinine between two groups（ P 〉0.05）. [Conclusion] MFF combined with tripterygium glycosides for the treatment of IgA nephropathy has definite clinical efficacy.
出处
《医学临床研究》
CAS
2011年第7期1295-1296,共2页
Journal of Clinical Research
